Technical Analysis for CLDX - Celldex Therapeutics, Inc.

Grade Last Price % Change Price Change
D 23.55 -0.04% -0.01
CLDX closed down 0.04 percent on Friday, April 16, 2021, on 40 percent of normal volume.
Earnings due: May 4
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Up
Historical CLDX trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.04%
Crossed Above 20 DMA Bullish -0.04%
MACD Bullish Signal Line Cross Bullish -0.04%
Wide Bands Range Expansion -0.04%
Up 3 Days in a Row Strength -0.04%
Up 4 Days in a Row Strength -0.04%
20 DMA Resistance Bearish 5.75%
Older End-of-Day Signals for CLDX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Celldex Therapeutics, Inc. Description

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. The company has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused precision targeted immunotherapy platform. Its lead drug candidates include rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma and a Phase II study for the treatment of recurrent glioblastoma; and CDX-011, an antibody-drug conjugate, which completed a randomized Phase IIb study for the treatment of advanced breast cancer. The company also has various earlier stage candidates in clinical development, such as CDX-1135, a molecule that inhibits a part of the immune system called the complement system; CDX-1127, a therapeutic fully human monoclonal antibody for cancer indications that is in Phase I study in patients with selected malignant solid tumors or hematologic cancers; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor, which completed Phase I study in healthy subjects; and CDX-1401, an antibody-targeted technology program for cancer indications that completed Phase I study in combination with toll-like receptor agonists poly-ICLC. Its preclinical product candidate includes CDX-014, a human monoclonal antibody-drug conjugate that targets TIM-1, a molecule that is expressed on renal and ovarian cancers with minimal expression in normal tissues. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Thomas Jefferson University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. Celldex Therapeutics, Inc. was founded in 1983 and is headquartered in Needham, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Cancer Clinical Medicine Immunology Clinical Development Solid Tumors Immune System Immunotherapy Treatment Of Cancer Monoclonal Antibody Monoclonal Antibodies Cancer Treatments Breast Cancer Genetics Treatment Of Breast Cancer Ovarian Cancer Blastoma Glioblastoma Antibody Drug Conjugates Cancer Center Brain Tumor Pivotal Cancer Research Complement System Dendritic Cell Ovarian Cancers Advanced Breast Cancer Hematologic Cancers Recurrent Glioblastoma Rockefeller University Targeted Immunotherapy

Is CLDX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 30.17
52 Week Low 2.12
Average Volume 719,763
200-Day Moving Average 17.71
50-Day Moving Average 24.53
20-Day Moving Average 22.61
10-Day Moving Average 21.77
Average True Range 1.90
ADX 23.6
+DI 23.56
-DI 25.32
Chandelier Exit (Long, 3 ATRs ) 21.14
Chandelier Exit (Short, 3 ATRs ) 21.07
Upper Bollinger Band 26.54
Lower Bollinger Band 18.68
Percent B (%b) 0.62
BandWidth 34.77
MACD Line -0.59
MACD Signal Line -0.83
MACD Histogram 0.2419
Fundamentals Value
Market Cap 931.81 Million
Num Shares 39.6 Million
EPS -3.74
Price-to-Earnings (P/E) Ratio -6.30
Price-to-Sales 114.73
Price-to-Book 3.74
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.40
Resistance 3 (R3) 25.40 24.78 25.09
Resistance 2 (R2) 24.78 24.31 24.78 24.98
Resistance 1 (R1) 24.17 24.02 23.86 24.17 24.88
Pivot Point 23.55 23.55 23.40 23.55 23.55
Support 1 (S1) 22.94 23.08 22.63 22.94 22.22
Support 2 (S2) 22.32 22.79 22.32 22.12
Support 3 (S3) 21.71 22.32 22.01
Support 4 (S4) 21.71